NCT00865579View on ClinicalTrials.gov

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

PHASE3TerminatedINTERVENTIONAL

Enrollment

964

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Parkinson's Disease

Interventions

DRUG

Safinamide

"The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning."

Trial Locations (1)

Unknown

Research Site, Timuș